BW
EFTRW

Boaz Weinstein’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Boaz Weinstein’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-34,836
Closed -$21K – 470
2021
Q1 		$21K Buy
+34,836
New +$33.6K ﹤0.01% 422

Other funds holding EFTRW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 374.31% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $157M AUM 29.28% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

Boaz Weinstein's EFTRW Position: Q2 2021 in Review

Boaz Weinstein sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q2 2021, closing a stake of 34,836 shares — an estimated $21K sold.

Boaz Weinstein first reported a position in EFTRW in Q1 2021 and held it in 1 quarter. The position peaked at $21K in Q1 2021. 38 funds tracked by Wall St. Rank hold EFTRW as of Q2 2021.

  • Boaz Weinstein reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q2 2021 after selling out during the quarter.
  • Boaz Weinstein sold 34,836 eFFECTOR Therapeutics, Inc. Warrant shares in Q2 2021, an estimated $21K.
  • Boaz Weinstein first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q1 2021 and held it in 1 quarter.
  • Boaz Weinstein's eFFECTOR Therapeutics, Inc. Warrant position peaked at $21K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q2 2021.

Based on Saba Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.